VBI Vaccines Resultados de beneficios anteriores
Pasado controles de criterios 0/6
VBI Vaccines's earnings have been declining at an average annual rate of -17.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 22.3% per year.
Información clave
-17.4%
Tasa de crecimiento de los beneficios
16.7%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 17.0% |
Tasa de crecimiento de los ingresos | 22.3% |
Rentabilidad financiera | n/a |
Margen neto | -892.5% |
Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
Sep 22VBI Vaccines gets up to $100M debt funding from K2 HealthVentures
Sep 15Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe
Sep 08VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings
Aug 26VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
Jun 17Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?
Jun 09Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?
Jan 24Desglose de ingresos y gastos
Cómo gana y gasta dinero VBI Vaccines. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
31 Mar 24 | 9 | -84 | 37 | 9 |
31 Dec 23 | 9 | -94 | 42 | 9 |
30 Sep 23 | 8 | -115 | 49 | 10 |
30 Jun 23 | 2 | -119 | 54 | 14 |
31 Mar 23 | 1 | -120 | 58 | 16 |
31 Dec 22 | 1 | -113 | 56 | 16 |
30 Sep 22 | 1 | -111 | 53 | 18 |
30 Jun 22 | 1 | -102 | 48 | 16 |
31 Mar 22 | 0 | -73 | 43 | 15 |
31 Dec 21 | 1 | -70 | 38 | 20 |
30 Sep 21 | 1 | -66 | 33 | 19 |
30 Jun 21 | 1 | -63 | 29 | 21 |
31 Mar 21 | 1 | -56 | 23 | 19 |
31 Dec 20 | 1 | -46 | 21 | 15 |
30 Sep 20 | 1 | -42 | 17 | 14 |
30 Jun 20 | 2 | -45 | 15 | 15 |
31 Mar 20 | 2 | -49 | 14 | 20 |
31 Dec 19 | 2 | -55 | 14 | 26 |
30 Sep 19 | 4 | -63 | 20 | 32 |
30 Jun 19 | 4 | -62 | 21 | 37 |
31 Mar 19 | 4 | -66 | 21 | 41 |
31 Dec 18 | 3 | -64 | 21 | 38 |
30 Sep 18 | 1 | -56 | 15 | 35 |
30 Jun 18 | 1 | -50 | 13 | 30 |
31 Mar 18 | 1 | -43 | 12 | 23 |
31 Dec 17 | 1 | -39 | 12 | 21 |
30 Sep 17 | 1 | -36 | 9 | 19 |
30 Jun 17 | 1 | -33 | 10 | 17 |
31 Mar 17 | 1 | -31 | 10 | 14 |
31 Dec 16 | 1 | -23 | 9 | 10 |
30 Sep 16 | 0 | -19 | 9 | 6 |
30 Jun 16 | 0 | -31 | 8 | 16 |
31 Mar 16 | 1 | -25 | 6 | 14 |
31 Dec 15 | 1 | -26 | 5 | 1 |
30 Sep 15 | 2 | -23 | 5 | 14 |
30 Jun 15 | 2 | -6 | 3 | 1 |
31 Mar 15 | 2 | -6 | 3 | 1 |
31 Dec 14 | 3 | -6 | 3 | 1 |
31 Dec 13 | 2 | -9 | 3 | 1 |
Ingresos de calidad: VBIV.Q is currently unprofitable.
Margen de beneficios creciente: VBIV.Q is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: VBIV.Q is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Acelerando crecimiento: Unable to compare VBIV.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: VBIV.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: VBIV.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.